SMNR (Semnur Pharmaceuticals) Interest Coverage: N/A (As of Mar. 2026)


SMNR Semnur Pharmaceuticals Inc SMNR
8 GF Score
Price $0.65
View Full Analysis

What is Semnur Pharmaceuticals Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Semnur Pharmaceuticals's Operating Income for the three months ended in Mar. 2026 was $-4.58 Mil. Semnur Pharmaceuticals's Interest Expense for the three months ended in Mar. 2026 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

The historical rank and industry rank for Semnur Pharmaceuticals's Interest Coverage or its related term are showing as below:


SMNR's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 106.07
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Semnur Pharmaceuticals  (OTCPK:SMNR) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Semnur Pharmaceuticals Interest Coverage Related Terms


Semnur Pharmaceuticals Interest Coverage Historical Data

* Premium members only.

The historical data trend for Semnur Pharmaceuticals's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Semnur Pharmaceuticals Interest Coverage Chart

Semnur Pharmaceuticals Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Interest Coverage
N/A N/A N/A N/A

Semnur Pharmaceuticals Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

SMNR vs CNTB, ENLV, MENS: Interest Coverage Comparison

For the Biotechnology subindustry, Semnur Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Semnur Pharmaceuticals Interest Coverage vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Semnur Pharmaceuticals's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Semnur Pharmaceuticals's Interest Coverage falls into.


SMNR
8GF Score
Semnur Pharmaceuticals Inc SMNR
Interest Coverage is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Semnur Pharmaceuticals Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Semnur Pharmaceuticals's Interest Coverage for the fiscal year that ended in Dec. 2025 is calculated as

Here, for the fiscal year that ended in Dec. 2025, Semnur Pharmaceuticals's Interest Expense was $0.00 Mil. Its Operating Income was $-160.42 Mil. And its Long-Term Debt & Capital Lease Obligation was $11.93 Mil.

GuruFocus does not calculate Semnur Pharmaceuticals's interest coverage with the available data.

Semnur Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Here, for the three months ended in Mar. 2026, Semnur Pharmaceuticals's Interest Expense was $0.00 Mil. Its Operating Income was $-4.58 Mil. And its Long-Term Debt & Capital Lease Obligation was $16.92 Mil.

GuruFocus does not calculate Semnur Pharmaceuticals's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Semnur Pharmaceuticals Business Description

Address 960 San Antonio Road, Palo Alto, CA, USA, 94303
Semnur Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its main product candidate, SP-102 (10 mg, dexamethasone sodium phosphate viscous gel), is being developed as a non-opioid novel injectable corticosteroid gel formulation for patients with moderate to severe LRP (also known as sciatica), containing no preservatives, surfactants, solvents, or particulates.
8GF Score

Get the complete analysis for SMNR

Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.65
Price